ClinicalTrials.gg
Not yet recruitingNCT07065695Updated Jul 15, 2025

Microscopic Varicocele Bypass Versus Ligation

An interventional study of transposition surgery and microscopic simple ligation in Varicocele, sponsored by Ke Dou. Not yet recruiting at 1 site in China. Open to male participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-07-15.

Sponsored by Ke Dou · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
284
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Male
01

Study summary

This study, titled "A Prospective Randomized Controlled Study on the Safety and Efficacy of Microscopic Varicocele Transposition Surgery Compared with Simple Ligation," is conducted by the Urology and Andrology Department of Sichuan Provincial People's Hospital, with Dou Ke serving as the principal investigator. The research period spans from May 2025 to December 2027. It aims to compare the outcomes of microscopic varicocele transposition surgery and simple ligation in treating left varicocele through a prospective randomized controlled trial, focusing on postoperative recovery, complications, semen quality, and other aspects to provide evidence for clinical surgical selection.

A total of 284 male patients will be enrolled, meeting criteria including clinical diagnosis of varicocele with surgical indications, aged 18-60 years, willing to participate and signing informed consent, abnormal semen analysis related to varicocele, no severe organ dysfunction, and no relevant treatments affecting the condition in the past three months. Exclusions include secondary varicocele, severe genitourinary or systemic diseases, coagulation disorders, drug allergies, mental/cognitive impairments, and participation in other related clinical trials. The experimental group will receive microscopic varicocele transposition surgery, while the control group will undergo microscopic simple ligation. Primary evaluation indicators include changes in spermatic vein diameter, reflux velocity, and duration assessed by color Doppler ultrasound at 1, 3, and 6 months post-surgery (with additional measurements of anastomotic vessel diameter and flow velocity in the experimental group), as well as pre- and post-surgery (3 and 6 months) semen routine parameters. Secondary indicators surgical success rate, postoperative complication rate, changes in reproductive hormone levels, pain relief evaluated by VAS scale, and quality of life improvements via specific assessment tools. Complying with the Declaration of Helsinki and approved by the ethics committee, informed consent will be obtained from all participants. Study results will be disseminated through academic papers, conference presentations, clinical research reports, and patient-focused summaries to advance new treatment directions for varicocele and optimize clinical protocols.

Read the detailed description

This prospective, single-blind, randomized controlled trial is conducted at the Urology and Andrology Center of Sichuan Provincial People's Hospital, led by Principal Investigator Dou Ke, to evaluate the safety and efficacy of microscopic varicocele transposition surgery compared with microscopic simple ligation for treating left varicocele. The study spans from May 2025 to December 2027.

  1. Study Design Details

    Randomization Process:

    Utilizing a computer-generated random number table with a 1:1 allocation ratio, patients are assigned to either group. To ensure randomness, the randomization sequence is generated by an independent statistician not involved in patient enrollment or intervention delivery. Block randomization with block sizes of 4-8 will be employed to balance group sizes over time.

    Blinding Implementation:

    In this single-blind design, patients remain unaware of their group assignment throughout the study. To maintain blinding, patient identification codes are used instead of names during follow-up, and outcome assessors are trained to conduct evaluations without accessing group allocation information. Surgeons and researchers directly involved in the surgical procedures are aware of the group assignment for proper procedure execution.

    Surgical Techniques:

    Experimental Group: Under 8-15× microscopic magnification, the surgical team will perform end-to-side or end-to-end anastomosis of the spermatic vein with other vessels, typically the inferior epigastric vein. The surgical procedure includes meticulous dissection to isolate the spermatic vein while carefully preserving the testicular artery, lymphatic vessels, and nerve fibers. Specialized microsurgical instruments, such as microscissors with a tip diameter of 0.1-0.3 mm and 10-11-0 nylon sutures, are used for precise anastomosis.

    Control Group: Microscopic simple ligation involves double ligation and division of the spermatic veins. The surgical field exposure, including the incision size (usually 3-4 cm), and the method of protecting testicular vasculature and other structures, are kept identical to the experimental group to minimize confounding factors.

  2. Measurement and Assessment Details

    Ultrasound Evaluation:

    Color Doppler ultrasound will be performed using high-resolution machines (e.g., with a probe frequency of 7-12 MHz) by experienced sonographers blinded to group assignment. For the experimental group, when assessing anastomotic vessel patency, the angle of insonation will be maintained at ≤60° to accurately measure blood flow velocity. Standardized scanning protocols will be followed, including specific patient positions (supine and standing) to detect varicocele reflux.

    Semen Analysis:

    Semen samples will be collected via masturbation after 2-7 days of sexual abstinence and analyzed within 1 hour at a certified andrology laboratory. Automated semen analyzers will be used to measure sperm concentration, motility, and morphology, while liquefaction time will be assessed visually. Quality control procedures, including periodic calibration of the analyzer and internal proficiency testing, are in place to ensure data reliability.

  3. Statistical Considerations

    Sample Size Calculation:

    Based on a previous study reporting a 15% difference in primary outcome improvement between similar surgical methods, with 80% power and a two-sided significance level of 0.05, a total sample size of 284 patients (142 per group) was determined. Adjustments for potential dropout rates (estimated at 10%) have been incorporated.

    Missing Data Handling:

    For continuous variables with missing data, multiple imputation methods will be used, considering baseline characteristics and other relevant variables. For categorical data, the last observation carried forward approach may be applied depending on the nature of missingness.

  4. Ethical and Safety Oversight

    Ethical Review:

    The study protocol has been reviewed and approved by the institutional ethics committee of Sichuan Provincial People's Hospital. An annual ethics review will be conducted to monitor any protocol deviations or emerging ethical issues.

    Safety Monitoring:

    An independent Data and Safety Monitoring Board (DSMB) will review interim safety data every 6 months. In case of a serious adverse event (SAE), such as testicular artery injury leading to ischemia, the DSMB can recommend immediate changes to the protocol, including halting the trial if necessary.

  5. Dissemination Plan

In addition to publishing in peer-reviewed urology and andrology journals and presenting at national/international conferences, the study team will collaborate with patient advocacy groups to develop infographics and short videos summarizing the key findings. These materials will be made available on the hospital's official website and social media platforms to enhance patient education and awareness.

02

Conditions studied

  • Varicocele

Browse trials for

Keywords

  • Varicocele
  • microscopic simple ligation
  • transposition surgery
03

In context

Varicocele

53 studies on the registry are indexed under Varicocele; 15 are open to participants now.

This study's planned enrollment of 284 is above the median of 72 across 36 interventional studies indexed under Varicocele.

Browse Varicocele studies →

Lead sponsor

This is the only study on the registry with Ke Dou as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with varicocele and meet the surgical indications
  • Male patients aged between 18 and 60 years old
  • Patients have the willingness to receive treatment, voluntarily participate in this study and sign the form
  • Semen analysis reveals abnormalities associated with varicocele
  • The patient has no severe dysfunction of vital organs and can tolerate surgery
  • The patient has received no relevant treatment affecting varicocele or semen quality in the past three months

Exclusion criteria

Exclusion Criteria:

  • Secondary varicocele
  • Complicated with other severe reproductive system diseases
  • Suffering from severe systemic diseases, which may affect the surgical effect or prognosis
  • Presence of coagulation dysfunction or taking medications that affect coagulation function
  • Having a history of allergy to the drugs used in the surgery
  • Having mental illness or cognitive impairment and being unable to cooperate to complete this study
  • Having already participated in other relevant clinical trials.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
284 participants (estimated)

Study arms

  • Experimental
    transposition surgery

    Reconstructs spermatic vein drainage via end to end anastomosis with inferior epigastric vein

    Procedure: transposition surgery

  • Active comparator
    simple ligation

    Blocks venous reflux via double ligation and division of spermatic veins under microscopy

    Procedure: microscopic simple ligation

Interventions

  • Proceduretransposition surgery

    Reconstructs spermatic vein drainage via end to side/end to end anastomosis with vessels (e.g., inferior epigastric vein) under 8-15× magnification, preserving testicular arteries/lymphatics.

  • Proceduremicroscopic simple ligation

    Blocks venous reflux via double ligation and division of spermatic veins under microscopy, with identical surgical exposure and vascular protection.

06

What researchers measure

Primary outcomes

  1. The effectiveness of the surgery

    measuring vein diameter,anastomotic vessel patency and reflux duration by color Doppler ultrasound

    Time frame: 1, 3, and 6 months postsurgery

  2. Semen analysis

    Semen Quality by semen analysis

    Time frame: 1, 3, and 6 months postsurgery

Secondary outcomes

  1. The incidence rate of postoperative complications

    Mainly include bleeding, testicular artery injury, scrotal hematoma and infection

    Time frame: postsurgery (3, 6 months)

  2. Testicular volume

    Measure the size of the testicles by ultrasound

    Time frame: postsurgery (3, 6 months)

  3. Testicular function

    Determination of serum sex hormones

    Time frame: postsurgery (3, 6 months)

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2025; primary completion for Jun 2027, 22 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2025
First posted
Jul 15, 2025
StartEst.
Jul 22, 2025
Primary completionEst.
Jun 1, 2027
CompletionEst.
Dec 31, 2027
Last update
Jul 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07065695
Lead sponsor
Ke Dou
Responsible party
Ke Dou (Sichuan Provincial People's Hospital, Sichuan Provincial People's Hospital) — Sponsor-investigator
First posted
Jul 15, 2025
Start date
Jul 22, 2025 (estimated)
Primary completion
Jun 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jul 15, 2025

Study contacts

Ke Dou, Ph.D
Contact
wangjiaa0420@sina.com
+862888132132

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion